Global Report on Diagnostic Partnership Agreements 2014-2021 | Structure of the agreement; Title, advance, stage and royalty data; Contract documents ; Top business by value; The most active negotiators

DUBLIN, November 19, 2021– (BUSINESS WIRE) – The report “Global Diagnostics 2014-2021 Partnership Terms and Agreements” has been added to ResearchAndMarkets.com offer.

This report provides comprehensive understanding and unprecedented access to diagnostic partnership agreements made by the world’s largest companies.

  • Trends in diagnostic transactions in the biopharmaceutical industry since 2014

  • Analysis of the structure of the Diagnostics transaction

  • Access to title, advance, milestone and royalty data

  • Access to contractual documents Diagnosis

  • Main diagnostic contracts in value since 2014

  • The most active diagnostic negotiators since 2014

This report details the latest diagnostic deals announced across healthcare sectors, covering:

  • Companion diagnosis

  • Imagery

  • CT

  • Endoscope

  • Molecular and nuclear

  • MRI

  • Ultrasound

  • x-ray

  • ANIMALS

  • SPECT

  • Angiography

  • Fluroscopy

  • Mammography

  • In vitro diagnostics

  • Molecular diagnosis

  • Prognosis

  • Theranostic

The report provides detailed understanding and analysis of how and why companies enter into partnership agreements with Diagnostics. These agreements tend to be multi-component, starting with collaborative R&D, and moving on to the commercialization of the results.

This report details the latest Diagnostics agreements announced in the life sciences since 2014.

The report presents the reader with a comprehensive review of diagnostic deal trends, key players, most important deal values, as well as deal financial data, helping to understand how, why, and under what terms, companies enter into deals. partnership agreements with Diagnostics.

The report presents the values ​​of financial agreement terms for diagnostic agreements, listing by aggregate value, upfront payments, milestone payments, and royalties, allowing readers to analyze and compare the financial value of the agreements.

The central section of the report explores the main negotiators in the area of ​​diagnostic partnerships; the values ​​of the most important transactions and the most active diagnostic trading companies are reported, allowing the reader to see who is successful in this dynamic trading market.

One of the highlights of the report is that over 3,600 online transaction records of actual diagnostic transactions, as disclosed by the parties to the transaction, are included towards the end of the report in a directory format – by AZ company, stage of development, type of transaction, therapeutic focus and type of technology – it’s easy to reference. Each transaction record in the report is linked via a web link to an online version of the transaction.

Additionally, when available, records include contractual documents as submitted to the Securities Exchange Commission by the companies and their partners. While many companies will be looking for details on payment terms, the devil is in the details of how payments are triggered – contract documents provide that insight where press releases and databases don’t. do not.

The first chapters of this report provide guidance for negotiating diagnostics. Chapter 1 provides an introduction to the report, while Chapter 2 provides an overview of diagnostic trading trends since 2014, including details on title terms, lead, milestones and royalties.

Chapter 3 reviews the main diagnostic offerings since 2014. Offerings are listed by aggregate value. When the deal has a deal contract published to the SEC, a link provides online access to the contract.

Chapter 4 provides a comprehensive list of the 25 Most Active in Diagnostic Transactions with a brief summary followed by a full list of diagnostic transactions advertised by this company, along with contract documents where applicable.

Chapter 5 provides a full and detailed review of the Diagnostics partnership agreements signed and announced since January 2014, where a contractual document is available in the public domain. Each transaction title is linked via a web link to an online version of the transaction record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a full and detailed review of the Diagnostics partnership agreements signed and announced since January 2014. The chapter is organized by specific Diagnostics technology type. Each transaction title is linked via a web link to an online version of the transaction record and, where applicable, the contract document, providing easy access to each transaction on demand.

A full set of appendices are provided, organized by Diagnostics AZ’s partner company, stage of development, type of agreement, and direction of therapy. Each transaction title is linked via a web link to an online version of the transaction record and, if applicable, the contract document, providing easy access to each transaction on demand.

The report also includes numerous tables and figures that illustrate the trends and the partnership and trading activities of Diagnostics since 2014.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of diagnostic technologies and products.

The 2014-2021 Global Diagnostics Partnership Terms and Agreements provide the reader with the following key benefits:

  • Deep understanding of diagnostic agreement trends since 2014

  • Access to title, advance, milestone and royalty data

  • Detailed access to real diagnostic contracts concluded by the main biopharmaceutical companies

  • Identify the most active diagnostic dealmakers since 2014

  • Overview of terms included in a Diagnostics partnership agreement, with concrete examples

  • Understand the key terms of agreements that companies have agreed to in previous agreements

  • Undertake due diligence to assess the adequacy of the terms of your proposed agreement for partner companies

Scope of the report

The 2014-2021 Global Diagnostics Partnership Terms and Agreements are intended to provide the reader with an in-depth understanding and access to Diagnostics trends and the structure of agreements entered into by leading companies around the world.

Under the terms and partnership agreements of Global Diagnostics 2014-2020, the available offers are listed by:

Each transaction title is linked via a web link to an online version of the transaction record and, if applicable, the contractual document, providing easy access to each contractual document on demand.

The Global Diagnostics Partnering Terms and Agreements 2014-2021 report provides full access to available offerings and contract documents for over 3,600 Diagnostics offerings.

The analysis of actual contractual agreements makes it possible to assess the following elements:

  • What are the specific rights granted or opted out?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the transaction?

  • How are sales and payments audited?

  • How long is the agreement?

  • How are the key terms of the agreement defined?

  • How are IPRs managed and held?

  • Who is responsible for marketing?

  • Who is responsible for development, sourcing and manufacturing?

  • How is confidentiality and publication managed?

  • How to resolve disputes?

  • Under what conditions can the deal be terminated?

  • What happens in the event of a change of owner?

  • What sub-licensing and subcontracting arrangements have been agreed?

  • What standard clauses does the company insist on?

  • Which standard clauses seem to differ from one partner to another or from one type of agreement to another?

  • What jurisdiction does the company insist on for the law of agreements?

The 2014-2021 Global Diagnostics Partnership Terms and Agreements provide the reader with the following key benefits:

  • Deep understanding of diagnostic agreement trends since 2014

  • Access to title, advance, milestone and royalty data

  • Detailed access to real diagnostic contracts concluded by the main biopharmaceutical companies

  • Identify the most active diagnostic dealmakers since 2014

  • Overview of terms included in a Diagnostics partnership agreement, with concrete examples

  • Understand the key terms of agreements that companies have agreed to in previous agreements

  • Undertake due diligence to assess the adequacy of the terms of your proposed agreement for partner companies

Companies mentioned

For more information on this report, visit https://www.researchandmarkets.com/r/rjrn6q

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211119005617/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Director
[email protected]

For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900


Source link

Comments are closed.